Journal: Epigenetics

Article Title: ANRIL upregulates TGFBR1 to promote idiopathic pulmonary fibrosis in TGF-β1-treated lung fibroblasts via sequestering let-7d-5p.

doi: 10.1080/15592294.2024.2435682

Figure Lengend Snippet: Figure 2. Knockdown of ANRIL inhibited TGF-b induced fibroblasts proliferation and activation. (a) The relative mRNA levels of Fn1, Col1a1, Col3a1, and Acta2 in ANRIL silenced MRC-5 cells after TGF-b induction; n = 3. (b) The relative protein levels of Fn1, Col1a1, Col3a1, and Acta2 in ANRIL silenced MRC-5 cells after TGF-β induction; n = 3. (c) EdU staining demonstrated the effect of ANRIL knockdown on lung fibroblast proliferation. Scale bar, 50 mm, n = 5. (d) Scratch assay for the evaluation of migration of lung fibroblasts after ANRIL knockdown. Scale bar, 200 mm, n = 5. (e) Immunofluorescence staining indicated that TGF-β1-induced a-sma positive cells were impeded by the reduced expression of ANRIL in MRC-5 fibroblasts. Scale bar, 50 mm, n = 5. Data are presented as mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001.

Article Snippet: Antibodies against TGFBR1 (1:1000, Proteintech 30,117–1-AP), Acta2 (1:2000, CST, #14968), FN1 (1:2000, CST, #26836), Col1a1 (1:2000, CST, #72026), Col3a1 (1:2000, CST, #30565) were used to detect proteins.

Techniques: Knockdown, Activation Assay, Staining, Wound Healing Assay, Migration, Immunofluorescence, Expressing

Journal: Epigenetics

Article Title: ANRIL upregulates TGFBR1 to promote idiopathic pulmonary fibrosis in TGF-β1-treated lung fibroblasts via sequestering let-7d-5p.

doi: 10.1080/15592294.2024.2435682

Figure Lengend Snippet: Figure 6. ANRIL promotes lung fibroblasts activation via TGFBR1. (a,b). The relative mRNA levels of Fn1, Col1a1, Col3a1, and Acta2 in MRC- 5 cells with different treatments after TGF-b induction, n = 3. (c,d). EdU results show the proliferation and migration of MRC-5 fibroblasts after different treatments, scale bar, 50 mm, n = 5. (e,f). wound healing assays show the proliferation and migration of MRC-5 fibroblasts after different treatments, scale bar, 50 mm, n = 5. Data are presented as mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001.

Article Snippet: Antibodies against TGFBR1 (1:1000, Proteintech 30,117–1-AP), Acta2 (1:2000, CST, #14968), FN1 (1:2000, CST, #26836), Col1a1 (1:2000, CST, #72026), Col3a1 (1:2000, CST, #30565) were used to detect proteins.

Techniques: Activation Assay, Migration

Journal: BMC Cancer

Article Title: The role of hepatocyte nuclear factor 4alpha in metastatic tumor formation of hepatocellular carcinoma and its close relationship with the mesenchymal–epithelial transition markers

doi: 10.1186/1471-2407-13-432

Figure Lengend Snippet: The expression of MET marks in primary tumors and their corresponding metastases suggested the occurrence of MET in the metastases. A) The number of the lesions with different staining intensity of the MET marks (including E-cadherin, N-cadherin, Fibronectin and Vimentin) in the primary tumors and their corresponding metastases. B) The expression change of MET marks in the metastases compared with their corresponding primary tumors (increased E-cadherin, decreased N-cadherin, Fibronectin and Vimentin expression), marking via the lines, showed the occurrence of MET in the metastases. C) The examples of the cases with increased E-cadherin, decreased N-cadherin, Fibronectin and Vimentin expression in the metastases compared with their primary tumors were showed. In the normal tumor-adjacent tissue, the expression of E-cadherin was mainly strong, but the expression of N-cadherin, Fibronectin and Vimentin was usually negative.

Article Snippet: After blocking, they were incubated overnight with E-cadherin (1:200, sc-8426, Santa Cruz Biotechnology, Santa Cruz, CA), Vimentin (1:100, Santa Cruz Biotechnology, Santa Cruz, CA), Fibronectin(1:100, sc-18825, Santa Cruz Biotechnology, Santa Cruz, CA), N-cadherin (1:100, Santa Cruz Biotechnology, Santa Cruz, CA), HNF4alpha (1:150, BS2983, Bioworld Technology), Snail (1:50, ab135708, Abcam Technology) or Slug (1:100, #9585, Cell Signaling Technology) primary antibodies.

Techniques: Expressing, Staining